Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab; Nivolumab; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Servier
- 02 Jun 2017 According to trial design data presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, the results of the dose-escalation part are expected in 2017.
- 02 Jun 2017 Trial design and recent update (as of Dec 2016) of this phase I study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Apr 2017 Planned number of patients changed from 54 to 94.